Since HLA-A*0201 is the most commonly expressed allele and expression of CT antigens are normally restricted to immunologically privileged male germ cells, targeting STK31 in CRC patients may be a promising immunotherapeutic approach, especially in metastatic patients. The gene discussed is HLA-A; the disease is colorectal carcinoma.